vs
Apellis Pharmaceuticals, Inc.（APLS）与EVgo Inc.（EVGO）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是EVgo Inc.的1.7倍（$199.9M vs $118.5M），EVgo Inc.净利率更高（-4.1% vs -29.5%，领先25.4%），EVgo Inc.同比增速更快（75.5% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-38.1M），过去两年EVgo Inc.的营收复合增速更高（46.6% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
EVgo Inc.是美国知名的电动汽车快充网络运营商，截至2023年8月，公司已布局超过950个充电站点，覆盖美国35个州，旗下充电桩兼容全球各大主流车企的电动汽车。
APLS vs EVGO — 直观对比
营收规模更大
APLS
是对方的1.7倍
$118.5M
营收增速更快
EVGO
高出81.4%
-5.9%
净利率更高
EVGO
高出25.4%
-29.5%
自由现金流更多
APLS
多$23.8M
$-38.1M
两年增速更快
EVGO
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $118.5M |
| 净利润 | $-59.0M | $-4.8M |
| 毛利率 | — | 38.0% |
| 营业利润率 | -25.6% | -10.4% |
| 净利率 | -29.5% | -4.1% |
| 营收同比 | -5.9% | 75.5% |
| 净利润同比 | -62.2% | 61.1% |
| 每股收益（稀释后） | $-0.40 | $-0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSEVGO
| Q4 25 | $199.9M | $118.5M | ||
| Q3 25 | $458.6M | $92.3M | ||
| Q2 25 | $178.5M | $98.0M | ||
| Q1 25 | $166.8M | $75.3M | ||
| Q4 24 | $212.5M | $67.5M | ||
| Q3 24 | $196.8M | $67.5M | ||
| Q2 24 | $199.7M | $66.6M | ||
| Q1 24 | $172.3M | $55.2M |
净利润APLSEVGO
| Q4 25 | $-59.0M | $-4.8M | ||
| Q3 25 | $215.7M | $-12.4M | ||
| Q2 25 | $-42.2M | $-13.0M | ||
| Q1 25 | $-92.2M | $-11.4M | ||
| Q4 24 | $-36.4M | $-12.4M | ||
| Q3 24 | $-57.4M | $-11.7M | ||
| Q2 24 | $-37.7M | $-10.4M | ||
| Q1 24 | $-66.4M | $-9.8M |
毛利率APLSEVGO
| Q4 25 | — | 38.0% | ||
| Q3 25 | — | 13.6% | ||
| Q2 25 | — | 14.2% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 14.5% | ||
| Q3 24 | — | 9.4% | ||
| Q2 24 | — | 9.6% | ||
| Q1 24 | — | 12.4% |
营业利润率APLSEVGO
| Q4 25 | -25.6% | -10.4% | ||
| Q3 25 | 48.7% | -36.9% | ||
| Q2 25 | -18.6% | -31.4% | ||
| Q1 25 | -50.0% | -44.4% | ||
| Q4 24 | -12.3% | -51.9% | ||
| Q3 24 | -24.0% | -47.1% | ||
| Q2 24 | -14.7% | -48.6% | ||
| Q1 24 | -36.0% | -58.7% |
净利率APLSEVGO
| Q4 25 | -29.5% | -4.1% | ||
| Q3 25 | 47.0% | -13.4% | ||
| Q2 25 | -23.6% | -13.3% | ||
| Q1 25 | -55.3% | -15.1% | ||
| Q4 24 | -17.1% | -18.4% | ||
| Q3 24 | -29.2% | -17.3% | ||
| Q2 24 | -18.9% | -15.6% | ||
| Q1 24 | -38.5% | -17.8% |
每股收益（稀释后）APLSEVGO
| Q4 25 | $-0.40 | $-0.03 | ||
| Q3 25 | $1.67 | $-0.09 | ||
| Q2 25 | $-0.33 | $-0.10 | ||
| Q1 25 | $-0.74 | $-0.09 | ||
| Q4 24 | $-0.30 | $-0.11 | ||
| Q3 24 | $-0.46 | $-0.11 | ||
| Q2 24 | $-0.30 | $-0.10 | ||
| Q1 24 | $-0.54 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $151.0M |
| 总债务越低越好 | — | $206.5M |
| 股东权益账面价值 | $370.1M | $-116.9M |
| 总资产 | $1.1B | $964.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSEVGO
| Q4 25 | $466.2M | $151.0M | ||
| Q3 25 | $479.2M | $181.3M | ||
| Q2 25 | $370.0M | $154.5M | ||
| Q1 25 | $358.4M | $150.0M | ||
| Q4 24 | $411.3M | $117.3M | ||
| Q3 24 | $396.9M | $141.9M | ||
| Q2 24 | $360.1M | $162.3M | ||
| Q1 24 | $325.9M | $175.1M |
总债务APLSEVGO
| Q4 25 | — | $206.5M | ||
| Q3 25 | — | $157.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSEVGO
| Q4 25 | $370.1M | $-116.9M | ||
| Q3 25 | $401.2M | $-428.1M | ||
| Q2 25 | $156.3M | $-230.1M | ||
| Q1 25 | $164.2M | $-36.8M | ||
| Q4 24 | $228.5M | $-256.1M | ||
| Q3 24 | $237.1M | $-344.8M | ||
| Q2 24 | $264.3M | $13.6M | ||
| Q1 24 | $266.7M | $25.7M |
总资产APLSEVGO
| Q4 25 | $1.1B | $964.8M | ||
| Q3 25 | $1.1B | $931.8M | ||
| Q2 25 | $821.4M | $864.7M | ||
| Q1 25 | $807.3M | $856.0M | ||
| Q4 24 | $885.1M | $803.8M | ||
| Q3 24 | $901.9M | $791.7M | ||
| Q2 24 | $904.5M | $785.3M | ||
| Q1 24 | $831.9M | $787.5M |
负债/权益比APLSEVGO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $11.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-38.1M |
| 自由现金流率自由现金流/营收 | -7.1% | -32.2% |
| 资本支出强度资本支出/营收 | 0.1% | 41.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-124.4M |
8季度趋势，按日历期对齐
经营现金流APLSEVGO
| Q4 25 | $-14.2M | $11.3M | ||
| Q3 25 | $108.5M | $-22.8M | ||
| Q2 25 | $4.4M | $14.1M | ||
| Q1 25 | $-53.4M | $-10.2M | ||
| Q4 24 | $19.4M | $-12.8M | ||
| Q3 24 | $34.1M | $12.1M | ||
| Q2 24 | $-8.3M | $7.6M | ||
| Q1 24 | $-133.0M | $-14.1M |
自由现金流APLSEVGO
| Q4 25 | $-14.3M | $-38.1M | ||
| Q3 25 | $108.3M | $-49.0M | ||
| Q2 25 | $4.4M | $-12.1M | ||
| Q1 25 | $-53.4M | $-25.2M | ||
| Q4 24 | $19.3M | $-36.5M | ||
| Q3 24 | — | $-13.7M | ||
| Q2 24 | $-8.4M | $-16.6M | ||
| Q1 24 | $-133.3M | $-35.2M |
自由现金流率APLSEVGO
| Q4 25 | -7.1% | -32.2% | ||
| Q3 25 | 23.6% | -53.1% | ||
| Q2 25 | 2.5% | -12.4% | ||
| Q1 25 | -32.0% | -33.5% | ||
| Q4 24 | 9.1% | -54.1% | ||
| Q3 24 | — | -20.3% | ||
| Q2 24 | -4.2% | -25.0% | ||
| Q1 24 | -77.3% | -63.7% |
资本支出强度APLSEVGO
| Q4 25 | 0.1% | 41.7% | ||
| Q3 25 | 0.0% | 28.3% | ||
| Q2 25 | 0.0% | 26.7% | ||
| Q1 25 | 0.0% | 19.9% | ||
| Q4 24 | 0.0% | 35.1% | ||
| Q3 24 | 0.0% | 38.3% | ||
| Q2 24 | 0.0% | 36.3% | ||
| Q1 24 | 0.2% | 38.2% |
现金转化率APLSEVGO
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EVGO
| Charging Network Revenue | $63.6M | 54% |
| Charging Revenue Retail | $35.8M | 30% |
| Charging Revenue Commercial | $9.3M | 8% |
| Charging Revenue Oem | $6.5M | 6% |
| Regulatory Credit Sales | $2.2M | 2% |
